Clinical
RSSArticles
-
HPV Testing: An Approach Whose Time Has Come?
A recent study found that genotyping for human papillomavirus 16/18 is a reasonable approach to help calculate the risk of progression to CIN3 or worse.
-
Hormonal Contraception: A Risk Factor for Depression?
A population-based study suggests that hormonal contraception increases the risk of treatment for depression, but bias provides a more likely explanation for the association.
-
What Every Prescriber Should Know: FDA’s Updated Warnings for Fluoroquinolone Antibiotics
Fluoroquinolones have risks and benefits that should be carefully considered before prescribing to patients for uncomplicated bacterial infections.
-
FDA Actions
In this section: The FDA adds warning label to testosterone products, approves new treatment for non-small cell lung cancer, greenlights drug for soft tissue sarcoma patients, and gives its blessing to the so-called 'artificial pancreas.'
-
Study: No Connection Between Cranberry Products, Fewer Urinary Tract Infections
The authors concluded that among older women who are nursing home residents, administration of cranberry capsules vs. placebo was of no benefit in preventing bacteriuria plus pyuria over one year.
-
Growing Evidence of Link Between Cognitive Dysfunction, Androgen Deprivation Therapy
The authors suggested androgen deprivation therapy in the treatment of prostate cancer may be associated with an increased risk of dementia.
-
CDC Calls for Two-shot HPV Regimen
Recent studies have shown if the first shot is administered before age 15, two shots confer immunity.
-
New Research Supports Safety of Receiving Vital Vaccination During Pregnancy
Infants exposed to combined tetanus, diphtheria, and acellular pertussis vaccinations were no more likely to develop structural birth defects, including microcephaly, than offspring of unvaccinated mothers.
-
Why Do the Beats Keep Changing?
What clinical situation commonly is associated with arrhythmias such as the one shown in this figure?
-
Adalimumab-atto Injection (Amjevita)
Adalimumab-atto provides an alternative to adalimumab for multiple chronic inflammatory conditions.